Palatin Technologies, Inc. (NASDAQ: PTN) will announce its first quarter fiscal year 2027 operating results on Tuesday, November 17, 2026, before the open of the U.S. financial markets.
Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 17 at 11:00 a.m. ET. The conference call will provide an update on corporate and development activities.
Palatin Technologies, Inc. is a biopharmaceutical company developing medicines targeting the melanocortin receptor system. Palatin's principal strategic development focus is advancing next-generation MC4R-selective agonists for rare neuroendocrine obesity disorders, including hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome.
Moreover, the Company is developing long-acting injectable peptide agonists, oral small-molecule agonists and an oral peptide agonist approach, with the objective of delivering differentiated efficacy, tolerability and dosing profiles suitable for long-term treatment. Palatin also utilizes collaborations, licensing arrangements and strategic partnerships to advance other melanocortin-based programs.
PTN shares faded six cents, or 9.1%, to $5.97.
